Treatment of 22Q11.2 deletion syndrome with cannabidiol
US11458109B2 · kind B2 · utility
3Cited by
4References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 2019 |
| Grant date | Oct 4, 2022 |
| Priority date | — |
| Expiry date | Jul 16, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.